Grail
American biotechnology and pharmaceutical company
GRAL Nasdaq
ISIN US3847471014 SEC CIK 1699031
Follow Grail
Weekly email: filings, results
Revenue, last quarter
$37.5M
+3.7% vs same quarter last year
Net income
−$103.6M
−16.4% vs same quarter last year
EPS, diluted
−$2.21
+10.2% vs same quarter last year
Operating cash flow
−$74.7M
−18.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $147.2M | −$408.4M |
| FY24 | $125.6M | −$2B |
| FY23 | $93.1M | −$1.5B |
| FY22 | $55.6M | −$5.4B |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −382% | −277.5% |
| FY24 | −1743% | −1613.9% |
| FY23 | −1627.6% | −1574.2% |
| FY22 | −9798.2% | −9719.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$299.9M |
| FY24 | −$582.4M |
| FY23 | −$608.7M |
| FY22 | −$584.2M |
- Grail
- Healthcare median
Show the numbers
| Year | Grail | Healthcare median |
|---|---|---|
| FY25 | −277.5% | −30.6% |
| FY24 | −1613.9% | −47% |
| FY23 | −1574.2% | −58% |
| FY22 | −9719.3% | −80.4% |